BIOSIMILARS CONGREGATION 2012
February 24, 2012(Ended)
Hilton Euston
London, United Kingdom
London, United Kingdom
The BIOSIMILARS CONGREGATION is a conference dedicated to the latest business models and strategies in the Biosimilar sector and cover topics suc as:
- Pharma and generics industries approach to the developing and emerging biosimilar market
- Challenges in clinical study design for biosimilar development
- Implications in current biologic drug development and patent protection
- The future of next generation Biosimilars
- Next generation monoclonal antibody development
- Biosimiliars and clinical trials solutions
- Pricing and reimbursement challenges to maximise the ROI
- Clinical challenges with biosimilar drug development
- Commercial challenges and opportunities
- Investments & potential returns from Biosimilars
- Recent successful strategies and business models
- Biosimilars Vs Bio-betters
- Regulatory framework in advanced and developing markets
- FDA`s current view of biosimilars
- Critical issues in demonstrating biosimilarity and maintaining diligent quality control
- EMA Regulatory Opinions on Treatment of mAbs
The BIOSIMILARS CONGREGATION brings together CMOs, CSOs, Presidents, Vice Presidents, Directors, Heads, Senior Scientists and Team Leaders from the following roles:
- Business Development
- Analytics
- Corporate Development Strategy
- Business Strategy
- Intellectual Property
- Commercial Affairs
- Medical Affairs
- Marketing & Sales
- Legal Affairs
- NewProduct Development
- Preclinical and Clinical Development
- CMC
- Regulatory Affairs
- Product Development
- Research and Development
- Pricing and Reimbursement
- Quality Assurance
- Biologic Production
- Strategic Planning
- Scientific Affairs
- Strategic Sourcing
Venue
Address
17-18 Upper Woburn Place,
Bloomsbury,
London,
United Kingdom
Bloomsbury,
London,
United Kingdom
Categories
Important
Please, check the conference website for possible changes, before you make any traveling
arrangements
* Prices are for evaluation only.
Articles/News/Press releases
